SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-011205
Filing Date
2022-06-06
Accepted
2022-06-06 13:35:51
Documents
15
Period of Report
2022-06-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20220606.htm   iXBRL 8-K 56877
2 EX-99.1 sabs-ex99_1.htm EX-99.1 16204
3 GRAPHIC img1871078_0.jpg GRAPHIC 15803
  Complete submission text file 0000950170-22-011205.txt   252909

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20220606.xsd EX-101.SCH 3259
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20220606_pre.xml EX-101.PRE 12789
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20220606_lab.xml EX-101.LAB 17242
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20220606_def.xml EX-101.DEF 13497
9 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20220606_htm.xml XML 6494
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 22997472
SIC: 2836 Biological Products, (No Diagnostic Substances)